rethinkTHC Search
Menu
Study breakdown

Medical cannabis reduced pain and improved sleep across rheumatology conditions

Cross SectionalModerate evidence
The takeaway

Among 319 rheumatology patients using medical cannabis, self-reported pain dropped by 57-83% and sleep quality improved by 71-87% across different conditions.

People with rheumatology conditions interested in medical cannabis outcomes, especially those with fibromyalgia or neuropathic pain.

77-83% pain reduction reported across most rheumatology conditions

What the researchers found

Patients with neuropathic problems reported the largest pain reduction (83%) and sleep improvement (87%), while those with inflammatory conditions saw the smallest pain reduction (57%). THC concentration, duration of use, and dosage each independently correlated with pain relief.

Why it matters

Rheumatology conditions like fibromyalgia are notoriously difficult to treat. This study captures real-world outcomes across multiple condition types within a single clinic population, offering a comparative snapshot of how different rheumatology patients respond to medical cannabis.

The numbers in context

351 patients located, 319 completed questionnaires. 82% had fibromyalgia. Mean pain reduction: 77% (fibromyalgia), 82% (mechanical), 83% (neuropathic), 57% (inflammatory). Mean sleep improvement: 78%, 71%, 87%, 76% respectively. Average monthly dose: 31-36g. Mean THC content: 18.38%.

How the study worked

Cross-sectional phone survey of 351 rheumatology clinic patients licensed for medical cannabis in Israel. Patients reported pain reduction and sleep improvement. Researchers analyzed correlations between cannabis parameters and outcomes.

What this study cannot tell us

Cross-sectional design with no control group. Self-reported outcomes subject to recall and placebo effects. Survivorship bias: patients who stopped cannabis were not captured. No standardized pain or sleep measurement tools used.

How to read the evidence

Moderate-sized patient sample but cross-sectional design with self-reported outcomes and no control group.

When this study was published

2021 study from Israeli rheumatology clinics.

The bigger picture

Self-reported outcomes this favorable need to be interpreted carefully, as patients who continue using cannabis are already a self-selected group. Still, the consistency of benefit across multiple rheumatology conditions suggests medical cannabis may have broad applicability in this patient population.

Questions still open

  • Would these results hold up in a controlled trial? Why did inflammatory conditions show the least pain reduction? What role does expectation bias play in self-reported cannabis outcomes?

Common questions

Which rheumatology condition responded best to medical cannabis?
Neuropathic problems showed the highest pain reduction (83%) and sleep improvement (87%), while inflammatory conditions showed the lowest pain reduction (57%).
What cannabis characteristics predicted better pain relief?
Higher THC concentration, longer duration of use, and higher consumption dose each independently correlated with greater pain reduction.

Read the original research

The Effect of Medical Cannabis on Pain Level and Quality of Sleep among Rheumatology Clinic Outpatients.

Pain research & management, 2021, 1756588

Citation

Habib, George; Khazin, Fadi; Artul, Suheil. (2021). The Effect of Medical Cannabis on Pain Level and Quality of Sleep among Rheumatology Clinic Outpatients.. Pain research & management, 2021, 1756588. https://doi.org/10.1155/2021/1756588

Explore the wider topic